G

ood morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today: hazelnut creme. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …

The White House is said to be drafting an executive order on drug pricing, according to BioCentury. The order will instruct executive agencies to use value-based contracts for purchasing medicines, and to pursue trade policies that enhance the intellectual property rights of American drug makers. There was no word, though, on other details or how soon the order may be completed.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • You all missed the bus ad imagery. Sage was just channeling Paul Simon; PPD may be one of of those 50 ways to leave your lover: “Just hop on the bus, Gus, don’t need to discuss much” (really can’t with that pacifier in your mouth).

  • An executive order on drug price$ – or should I say ‘Another Executive Order, this time on drug prices.” I guess hoping for some good legislation on the topic is out of the question but once again, ‘style over substance.’

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy